Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer

Video

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Although trastuzumab (Herceptin) remains the standard of care, the recent approval of neratinib could shake up treatment decisions for certain subgroups of breast cancer.

Related Videos
Bernard A. Fox, PhD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus
Jameel Muzaffar, MD
Hannah Walker-Mimms, MS
Hye Sook Chon, MD, gynecologic oncologist, Gynecologic Oncology Program, Moffitt Cancer Center
Amma Asare, MD, PhD
Sundar Jagannath, MBBS
Elias Jabbour, MD
Rebecca Klisovic, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Related Content
consultant medical oncologist at Portsmouth Hospital NHS Trust

NICE Recommends Oncotype DX for Guiding Chemotherapy Decisions in Early-Stage, HR+/HER2– Breast Cancer

May 10th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Nathalie LeVasseur, MD, FRCPC

Health Canada Approves Goserelin Acetate for High-Risk, ER+ Early and Advanced Breast Cancer

May 8th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Antonio Llombart-Cussac, MD, PhD

Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

May 1st 2024
Article
3d rendered illustration - breast cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Final USPSTF Recommendation Statement Advises Women Begin Receiving Mammograms at 40 Years Old

May 1st 2024
Article